BioStock

Prenumeration

BioStock: CombiGene's new agreement important for future clinical studies

2020-09-11 14:17:40

The Gene therapy company CombiGene announced yesterday that an agreement has been signed with CDMO manufacturer Cobra Biologics, regarding GMP production of two of the essential plasmids needed for the production of the company's drug candidate CG01. In doing so, the company is taking a step closer to clinical studies with CG01 and a future treatment for drug-resistant focal epilepsy.

Read the full article about CombiGene at biostock.se:

https://www.biostock.se/en/combigenes-new-agreement-important-for-future-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden